http://orcid.org/0000-0002-1387-0932
References
- Caruso S, Agnello C, Intelisano G, et al. Sexual behavior of women taking low-dose oral contraceptive containing 15 µg ethinylestradiol/60 µg gestodene. Contraception. 2004;69:237–240.
- Weisberg E. Contraceptive options for women in selected circumstances. Best Pract Res Clin Obstet Gynaecol. 2010;24:593–604.
- Caruso S, Malandrino C, Cicero C, et al. Quality of sexual life of women on oral contraceptive continued-regimen: pilot study. J Sex Med. 2013;10:460–466.
- Brache V, Faundes A. Contraceptive vaginal rings: a review. Contraception. 2010;82:418–427.
- Nuvaring SPC [product monograph]; 2017 Apr 7 [cited 2017 Jul 7]. Available from: http://www.medicines.org.uk/emc/medicine/21419
- Brache V, Pay An JL, Faundes A. Current status of contraceptive vaginal rings. Contraception. 2013;87:264–272.
- Bruni V, Pontello V, Luisi S, et al. An open-label, multicentre trial to evaluate the vaginal bleeding pattern of the combined contraceptive vaginal ring NuvaRing. Eur J Obstet Gynecol Reprod Biol. 2008;139:65–71.
- Algorta J, Diaz M, de Benito R, et al. Pharmacokinetic bioequivalence, safety and acceptability of Ornibel®, a new polymer composition contraceptive vaginal ring (etonogestrel/ethinylestradiol 11.00/3.474 mg) compared with Nuvaring® (etonogestrel/ethinylestradiol 11.7/2.7 mg). Eur J Contracept Reprod Health Care. 2017;22:429–438.
- Caruso S, Cianci S, Malandrino C, et al. Quality of sexual life of women using the contraceptive vaginal ring in extended cycles: preliminary report. Eur J Contracept Reprod Health Care. 2014;19:307–314.
- Nappi RE, Albani F, Vaccaro P, et al. Use of the Italian translation of the Female Sexual Function Index (FSFI) in routine gynecological practice. Gynecol Endocrinol. 2008;24:214–219.
- Derogatis LR, Rosen R, Leiblum S, et al. The Female Sexual Distress Scale (FSDS): initial validation of a standardized scale for assessment of sexually related personal in distress women. J Sex Marital Ther. 2002;28:317–330.
- Ware JE, Kosinski M, Gandek B, et al. The factor structure of the SF-36 Health Survey in 10 countries: results from the International Quality of Life Assessment (IQOLA) project. J Clin Epidemiol. 1998;51:1159–1165.
- Gallagher EJ, Liebman M, Bijur PE. Prospective validation of clinically important changes in pain severity measured on a visual analog scale. Ann Emerg Med. 2001;38:633–638.
- Timmer CJ, Mulders T. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clin Pharmacokinet. 2000;39:233–242.
- Weisberg E, Fraser IS, Lacarra M, et al. Efficacy, bleeding patterns, and side effects of a 1-year contraceptive vaginal ring. Contraception. 1999;59:311–318.
- Caruso S, Cianci S, Vitale SG, et al. Sexual function and quality of life of women adopting the levonorgestrel-releasing intrauterine system (LNG-IUS 13.5 mg) after abortion for unintended pregnancy. Eur J Contracept Reprod Health Care. 2018;23:24–31.
- Caruso S, Cianci S, Cariola M, et al. Improvement of low sexual desire due to antiandrogenic combined oral contraceptives after switching to an oral contraceptive containing 17β-estradiol. J Womens Health (Larchmt). 2017;26:728–734.
- van den Heuvel M, van Bragt A, Alnabawy A, et al. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception. 2005;72:168–174.
- Caruso S, Iraci Sareri M, Agnello C, et al. Conventional vs. extended-cycle oral contraceptives on the quality of sexual life: comparison between two regimens containing 3 mg drospirenone and 20 μg ethinyl estradiol. J Sex Med. 2011;8:1478–1485.
- Caruso S, Agnello C, Intelisano G, et al. Prospective study on sexual behavior of women using 30 microgethinylestradiol and 3 mg drospirenone oral contraceptive. Contraception. 2005;72:19–23.